Thursday, November 12, 2026

Palladium Futures Over 13% Down In The Last 21 Sessions

Palladium Futures Over 13% Down In The Last 21 Sessions

(VIANEWS) - Palladium (PA) has been up by 13.63% for the last 21 sessions. At 14:51 EST on Friday, 3 May, Palladium (PA) is $947.50.

Volume

Today's last reported volume for Palladium is 4092, 99.99% below its average volume of 3453387877.9.

Volatility

Palladium's last week, last month's, and last quarter's current intraday variation average was 0.87%, 0.39%, and 1.89%, respectively.

Palladium's highest amplitude of average volatility was 2.22% (last week), 1.50% (last month), and 1.89% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palladium's commodity is considered to be oversold (<=20).

News about

  • According to FXStreet on Thursday, 2 May, "The Mexican Peso (MXN) trades higher in its key pairs on Thursday as market sentiment gets a lift from a combination of factors, including the US Federal Reserve's (Fed) decision to maintain an easing bias at its policy meeting on Wednesday, and Crude Oil prices hovering close to seven-week lows.", "Lower Crude Oil prices, with WTI trading in the mid $79s, were a further positive factor for global risk sentiment as they reduce companies' transportation and energy costs."
  • Crude oil recedes post-fed, WTI tumbles below $80. According to FXStreet on Wednesday, 1 May, "This week's EIA print represents the highest WoW Crude Oil buildup since the week ended February 9. ", "With most global markets focused on the Fed's latest rate call, the Energy Information Administration (EIA) printed its latest week-on-week barrel counts for US Crude Oil supply. "

More news about Palladium (PA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com